Diabetes: Glycated hemoglobin is a marker of diabetes and CVD risk

Nature Reviews Cardiology

Volumn 7, Issue 7, 2010, Pages 367-368

  Wareham, Nicholas J ^a   Pfister, Roman ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE MARKER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 77954149685     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.84     Document Type: Short Survey

References (10)

1. Gerstein, H. C. et al. effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 121, 1176-1187 (2010).
2. nissen, s. e. et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PeRisCOPe randomized controlled trial. JAMA 299, 1561-1573 (2008).
3. Dormandy, J. A. et al. secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial in macrovascular events): a randomised controlled trial. Lancet 366, 1279-1289 (2005).
4. nissen, s. e. & wolski, K. effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007).
5. Home, P. D. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (ReCORD): a multicenter, randomised, openlabel trial. Lancet 373, 2125-2135 (2009).
6. BARi 2D study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360, 2503-2515 (2009).
7. niH. Thiazolidinedione intervention with vitamin D evaluation (TiDe). Trial identifier: nCT00879970. ClinicalTrials.gov [online], http:// clinicaltrials.gov/ct2/show/ nCT00879970 (2010).
8. Goldberg, R. B. et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28, 1547-1554 (2005).
9. vijay, s. K., Mishra, M., Kumar, H. & Tripathi, K. effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol. 46, 27-33 (2009).
10. Mikhail, n. incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin. Investig. Drugs 17, 845-853 (2008).